Breaking News Instant updates and real-time market news.

FOLD

Amicus

$15.83

0.15 (0.96%)

20:57
02/15/18
02/15
20:57
02/15/18
20:57

Amicus 19.355M share Secondary priced at $15.50

The deal size was increased to $300M in common stock from $250M in common stock. JPMorgan, Goldman Sachs, Cowen and Leerink acted as joint book running managers for the offering.

  • 13

    Aug

  • 12

    Sep

  • 16

    Feb

FOLD Amicus
$15.83

0.15 (0.96%)

08/17/17
JPMS
08/17/17
NO CHANGE
JPMS
JPMorgan lists top SMID Biotechnology picks following Q2 results
Analysts at JPMorgan continue think selectively remains important in the small-to-mid cap Biotechnology space. The analysts listed their favorite ideas in "five key buckets." Amicus (FOLD) is the top long-term pick, Ironwood (IRWD) is the top pick among relative underperformers, Otonomy (OTIC) is the top play for a clinical/binary event, Sarepta (SRPT) is the name to take advantage of the recent share weakness, and Ignyta (RXDX) is the "underfollowed/undervalued" favorite, according to JPMorgan's Biotech team.
09/14/17
BARD
09/14/17
NO CHANGE
Target $16
BARD
Outperform
Amicus SD-101 failure disappointing, but removes key overhang, says Baird
Baird analyst Michael Ulz noted Amicus reported its SD-101 Phase 3 study missed all of its endpoints. Although disappointing, the trial was given a low probability of success. This news removes a key overhang for the company, setting up additional upside with its Pompe program, Ulz tells investors. He remains encouraged by the early data from the Pompe program, which should be releasing full six-month data later this month. Ulz reiterated his Outperform rating and raised his price target to $16 from $15 on Amicus shares.
09/15/17
JPMS
09/15/17
NO CHANGE
Target $15
JPMS
Overweight
JPMorgan continues to see upside in Amicus shares
JPMorgan analyst Anupam Rama says Amicus Therapeutics remains one of his top picks, and that he continues to see upside from current share levels, ahead of the upcoming Pompe data readout. The analyst sees a high probability that the Q3 data update will meet or exceed the efficacy benchmarks, leading to increased probability of success/revenue estimates across Street models. His base case, with a 75% probability of success assumption, still provides for 10%-15% upside from current share levels. His "homerun scenario," which is maintaining the 6MWD benefit shown in Q2 or better, has the stock rallying 35%-40%.
10/04/17
BOFA
10/04/17
NO CHANGE
Target $20
BOFA
Buy
Amicus price target raised to $20 from $15 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Amicus' price target to $20 from $15 saying the Phase 1/2 trial results of ATB200/AT2221 in Pompe disease were impressive. The analyst thinks the strong data justifies progression into pivotal trials and may result in an accelerated approval path. Ahmad rates Amicus a Buy.

TODAY'S FREE FLY STORIES

DRI

Darden

$116.11

7.485 (6.89%)

05:53
03/22/19
03/22
05:53
03/22/19
05:53
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$17.35

1.29 (8.03%)

05:43
03/22/19
03/22
05:43
03/22/19
05:43
Upgrade
Commercial Metals rating change  »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$134.59

2.69 (2.04%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

BBY

Best Buy

$70.56

1.44 (2.08%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Best Buy rating change  »

Best Buy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAR

Varian Medical

$137.77

1.97 (1.45%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Varian Medical rating change  »

Varian Medical upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Downgrade
Biogen rating change  »

Citi downgrades Biogen to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

FTI

TechnipFMC

$23.83

0.09 (0.38%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RYB

RYB Education

$8.01

0.09 (1.14%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Downgrade
RYB Education rating change  »

RYB Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOV

Spark Networks

$11.29

(0.00%)

05:26
03/22/19
03/22
05:26
03/22/19
05:26
Conference/Events
Spark Networks to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

ESALY

Eisai

$0.00

(0.00%)

05:25
03/22/19
03/22
05:25
03/22/19
05:25
Downgrade
Eisai rating change  »

Eisai downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$0.00

(0.00%)

, BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:24
03/22/19
03/22
05:24
03/22/19
05:24
Hot Stocks
Eisai announces initiation of Phase III BAN2401 study in Alzheimer's disease »

Eisai (ESALY) announced…

ESALY

Eisai

$0.00

(0.00%)

BIIB

Biogen

$226.71

-93.76 (-29.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

ZUO

Zuora

$24.34

0.62 (2.61%)

05:18
03/22/19
03/22
05:18
03/22/19
05:18
Recommendations
Zuora analyst commentary at Jefferies »

Zuora business metrics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

OPHRY

Ophir Energy

$0.00

(0.00%)

05:15
03/22/19
03/22
05:15
03/22/19
05:15
Downgrade
Ophir Energy rating change  »

Ophir Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:13
03/22/19
03/22
05:13
03/22/19
05:13
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KGFHY

Kingfisher

$0.00

(0.00%)

05:13
03/22/19
03/22
05:13
03/22/19
05:13
Downgrade
Kingfisher rating change  »

Kingfisher downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$31.29

0.78 (2.56%)

05:11
03/22/19
03/22
05:11
03/22/19
05:11
Earnings
Health Insurance confirms 2019 outlook, calls shares 'compelling value' »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HIIQ

Health Insurance Innovations

$31.29

0.78 (2.56%)

05:07
03/22/19
03/22
05:07
03/22/19
05:07
Hot Stocks
Health Insurance CEO says multi-state regulatory review found no issues »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

PSO

Pearson

$10.96

0.07 (0.64%)

05:02
03/22/19
03/22
05:02
03/22/19
05:02
Upgrade
Pearson rating change  »

Pearson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$52.05

2.395 (4.82%)

04:59
03/22/19
03/22
04:59
03/22/19
04:59
Upgrade
Lumentum rating change at JPMorgan »

Lumentum upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

PPG

PPG

$112.60

1.73 (1.56%)

04:58
03/22/19
03/22
04:58
03/22/19
04:58
Downgrade
PPG rating change at JPMorgan »

PPG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

SHW

Sherwin-Williams

$433.70

4.385 (1.02%)

04:57
03/22/19
03/22
04:57
03/22/19
04:57
Downgrade
Sherwin-Williams rating change at JPMorgan »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

MDB

MongoDB

$154.52

10.73 (7.46%)

04:55
03/22/19
03/22
04:55
03/22/19
04:55
Initiation
MongoDB initiated at William Blair »

MongoDB initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
03/22/19
03/22
04:55
03/22/19
04:55
General news
Breaking General news story  »

Week of 3/22 Baker-Hughes…

04:55
03/22/19
03/22
04:55
03/22/19
04:55
General news
Wholesale Trade Inventories to be reported at 10:00 »

January Wholesale Trade…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.